Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41531-025-01230-6 http://scihub22266oqcxt.onion/10.1038/s41531-025-01230-6 41366251!?!41366251 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41366251&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       NPJ+Parkinsons+Dis 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41366251|t=2025. Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson s disease patients |pdf=|usr=}}{{41366251}} gab.com Text Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson s disease patients JO: NPJ Parkinsons Dis http://www.kidney.de/pget.php?&tw=1&pmid=41366251 #FOAvip In models of Parkinson's disease (PD), angiotensin-II type-1 receptor (AT1) blockers (ARBs) mitigated the vulnerability of dopaminergic neurons, which aligns with recent transcriptomic studies of human brains showing increased susceptibility of dopaminergic neurons with high AGTR1 expression, and with epidemiological data indicating an ARB-related reduction in PD incidence. However, there is no experimental evidence in PD patients. Using a minimally invasive strategy based on the isolation of blood extracellular vesicles (EVs) from neuronal, microglial/macrophage, astrocytic, and oligodendrocytic origin, we report proteomic profiles from patients treated with the ARB candesartan. Candesartan treatment led to the differential expression of key proteins involved in PD pathogenesis: 46 in neuron-derived EVs, 48 in microglia/macrophage-derived EVs, 22 in astrocyte-derived EVs, and 92 in oligodendrocyte-derived EVs. Our findings provide the first direct molecular evidence of neuroprotective mechanisms triggered by ARBs in PD patients and support the rationale for larger clinical trials on ARB repurposing. Twit Text FOAVip Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson s disease patients ????NPJ Parkinsons Dis http://www.kidney.de/pget.php?&tw=1&pmid=41366251 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41366251 #FOAvip English Wikipedia <ref>{{Cite pmid|41366251}}</ref> Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson s disease patients #MMPMID41366251 Camacho-Meno L; Labandeira CM; Bravo SB; Torres MV; Bejr-Kasem H; Molina-Crespo A; Atienza M; Lanciego JL; Cantero JL; Kulisevsky J; Labandeira-Garcia JL; Rodriguez-Perez AI NPJ Parkinsons Dis 2025[Dec]; ? (?): ? PMID41366251show ga In models of Parkinson's disease (PD), angiotensin-II type-1 receptor (AT1) blockers (ARBs) mitigated the vulnerability of dopaminergic neurons, which aligns with recent transcriptomic studies of human brains showing increased susceptibility of dopaminergic neurons with high AGTR1 expression, and with epidemiological data indicating an ARB-related reduction in PD incidence. However, there is no experimental evidence in PD patients. Using a minimally invasive strategy based on the isolation of blood extracellular vesicles (EVs) from neuronal, microglial/macrophage, astrocytic, and oligodendrocytic origin, we report proteomic profiles from patients treated with the ARB candesartan. Candesartan treatment led to the differential expression of key proteins involved in PD pathogenesis: 46 in neuron-derived EVs, 48 in microglia/macrophage-derived EVs, 22 in astrocyte-derived EVs, and 92 in oligodendrocyte-derived EVs. Our findings provide the first direct molecular evidence of neuroprotective mechanisms triggered by ARBs in PD patients and support the rationale for larger clinical trials on ARB repurposing. ?Brain-derived extracellular vesicle proteomics reveals neuroprotection(epmc).pdf DeepDyve Pubget Overpricing